Literature DB >> 25417201

Comparative study of different procedures for the separation of peripheral blood mononuclear cells in cytokine-induced killer cell immunotherapy for hepatocarcinoma.

Hui Liu1, Jianyu Li, Fengmei Wang, Yingtang Gao, Ying Luo, Peng Wang, Chenglong Li, Zhengyan Zhu.   

Abstract

Cytokine-induced killer (CIK) cell immunotherapy exhibits significant advantages in the clinical treatment of tumors. This study was designed to compare the biological characteristics of autologous CIK cells from patients with hepatocarcinoma following different procedures for the separation of peripheral blood mononuclear cells (PBMCs). Forty-four hepatocarcinoma patients were enrolled and distributed into two groups. PBMCs were isolated either using a blood cell separator (apheresis method) or Ficoll lymphocyte separation medium (Ficoll method). The total amount, collection efficacy, and cell status of PBMCs in the two groups were determined. According to the number and status of collected PBMCs, different cultivation procedures were used for their amplification and activation and the proliferation ability, phenotype, and killing activity of CIK cells in the two groups were evaluated. Our results indicated that the number of collected PBMCs in the apheresis group was far more than that in the Ficoll group. However, the isolation rate was lower, and more cellular debris was observed in the apheresis group, which may be the cause of some untoward effects. Following in vitro culture, the enrichment time of CIK cells was longer in the Ficoll group, and the percentages of CD3(+)CD4(+) (Th) and CD4(+)CD25(+) (Treg) cells were higher. In the apheresis group, the percentages of CD3(-)CD56(+) (NK) and CD3(+)CD56(+) (NKT) cells were higher, and the CIK cells exhibited a higher cytolytic activity against HepG2 hepatoma cells. In conclusion, different procedures for PBMCs separation can influence the biological activities of CIK cells, and the apheresis method is more effective at enhancing the antitumor efficacy of CIK cells. However, significant attention should be paid to the possibility of adverse reactions in apheresis donors.

Entities:  

Mesh:

Year:  2014        PMID: 25417201     DOI: 10.1007/s13277-014-2837-5

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  36 in total

1.  IL-7 abrogates suppressive activity of human CD4+CD25+FOXP3+ regulatory T cells and allows expansion of alloreactive and autoreactive T cells.

Authors:  Anne-Kristin Heninger; Anke Theil; Carmen Wilhelm; Cathleen Petzold; Nicole Huebel; Karsten Kretschmer; Ezio Bonifacio; Paolo Monti
Journal:  J Immunol       Date:  2012-11-05       Impact factor: 5.422

2.  Comparative study on anti-tumor immune response of autologous cytokine-induced killer (CIK) cells, dendritic cells-CIK (DC-CIK), and semi-allogeneic DC-CIK.

Authors:  Qi-Jing Wang; Hui Wang; Ke Pan; Yong-Qiang Li; Li-Xi Huang; Shi-Ping Chen; Jia He; Miao-La Ke; Jing-Jing Zhao; Jian-Jun Li; Jian-Cong Sun; Xiao-Ting Liang; Hai-Qing Ma; Yi-Bing Chen; Jian-Chuan Xia
Journal:  Chin J Cancer       Date:  2010-07

Review 3.  Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors.

Authors:  Giulia Mesiano; Maja Todorovic; Loretta Gammaitoni; Valeria Leuci; Lidia Giraudo Diego; Fabrizio Carnevale-Schianca; Franca Fagioli; Wanda Piacibello; Massimo Aglietta; Dario Sangiolo
Journal:  Expert Opin Biol Ther       Date:  2012-04-14       Impact factor: 4.388

4.  Inhibition of peripheral blood natural killer cell cytotoxicity in patients with myasthenia gravis treated with plasmapheresis.

Authors:  P J Chien; J H Yeh; H C Chiu; Y M Hsueh; C T Chen; M C Chen; C M Shih
Journal:  Eur J Neurol       Date:  2011-05-07       Impact factor: 6.089

5.  Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells.

Authors:  Jeffrey W Leong; Julie M Chase; Rizwan Romee; Stephanie E Schneider; Ryan P Sullivan; Megan A Cooper; Todd A Fehniger
Journal:  Biol Blood Marrow Transplant       Date:  2014-01-13       Impact factor: 5.742

6.  Cytotoxic difference of T cells expanded with anti-CD3 monoclonal antibody in the presence and absence of anti-CD 28 monoclonal antibody.

Authors:  Yoshiko Yamada-Ohnishi; Hiroshi Azuma; Noriko Urushibara; Miki Yamaguchi; Mitsuhiro Fujihara; Tetsuji Kobata; Hisami Ikeda
Journal:  Stem Cells Dev       Date:  2004-06       Impact factor: 3.272

Review 7.  Application of IL-2 therapy to target T regulatory cell function.

Authors:  Ethan M Shevach
Journal:  Trends Immunol       Date:  2012-08-30       Impact factor: 16.687

8.  CD3 antibody and IL-2 complex combination therapy inhibits atherosclerosis by augmenting a regulatory immune response.

Authors:  Kazuyuki Kasahara; Naoto Sasaki; Tomoya Yamashita; Tomoyuki Kita; Keiko Yodoi; Yoshihiro Sasaki; Masafumi Takeda; Ken-Ichi Hirata
Journal:  J Am Heart Assoc       Date:  2014-04-22       Impact factor: 5.501

Review 9.  Adoptive immunotherapy in postoperative hepatocellular carcinoma: a systemic review.

Authors:  Feng Xie; Xinji Zhang; Hui Li; Tao Zheng; Feng Xu; Rongxi Shen; Long Yan; Jiamei Yang; Jia He
Journal:  PLoS One       Date:  2012-08-15       Impact factor: 3.240

10.  Sunitinib indirectly enhanced anti-tumor cytotoxicity of cytokine-induced killer cells and CD3⁺CD56⁺ subset through the co-culturing dendritic cells.

Authors:  Adisak Wongkajornsilp; Valla Wamanuttajinda; Kanda Kasetsinsombat; Sunisa Duangsa-ard; Khanit Sa-ngiamsuntorn; Suradej Hongeng; Kittipong Maneechotesuwan
Journal:  PLoS One       Date:  2013-11-13       Impact factor: 3.240

View more
  6 in total

1.  The effects of hemocyanin on T cells cultured in vitro.

Authors:  Jiani Liu; Cong Chen; Chen Ling; Haoyun Hu; Jingsong Cao; Yongqiang Gao
Journal:  Oncol Lett       Date:  2017-12-11       Impact factor: 2.967

2.  Influence of different ex vivo cell culture methods on the proliferation and anti-tumor activity of cytokine-induced killer cells from gastric cancer patients.

Authors:  Bin Shi; Aixia Sun; Xiaorui Zhang
Journal:  Onco Targets Ther       Date:  2018-05-08       Impact factor: 4.147

3.  Adjuvant immunotherapy of dendritic cells and cytokine-induced killer cells is safe and enhances chemotherapy efficacy for multiple myeloma in China: a meta-analysis of clinical trials.

Authors:  Yan Wang; Benji Lv; Ke Li; Anqi Zhang; Hong Liu
Journal:  Drug Des Devel Ther       Date:  2017-11-15       Impact factor: 4.162

4.  Phenotypic and functional stability of leukocytes from human peripheral blood samples: considerations for the design of immunological studies.

Authors:  Adriana Navas; Lina Giraldo-Parra; Miguel Darío Prieto; Juliana Cabrera; María Adelaida Gómez
Journal:  BMC Immunol       Date:  2019-01-18       Impact factor: 3.615

5.  Clinical applications of dendritic cells-cytokine-induced killer cells mediated immunotherapy for pancreatic cancer: an up-to-date meta-analysis.

Authors:  Yucai Zhang; Xiaorui Zhang; Anqi Zhang; Ke Li; Kai Qu
Journal:  Onco Targets Ther       Date:  2017-08-23       Impact factor: 4.147

6.  FOLFOX regimen plus dendritic cells-cytokine-induced killer cells immunotherapy for the treatment of colorectal cancer: a meta-analysis.

Authors:  Yan Liu; Zhong Zheng; Qixin Zhang; Xinling Zhou; Yikuan Feng; Anquan Yan
Journal:  Onco Targets Ther       Date:  2017-05-18       Impact factor: 4.147

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.